Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

VANCOUVER, July 16 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Liberte(R) Long Paclitaxel-Eluting Coronary Stent System, a next-generation drug-eluting stent (DES) designed for long lesions. At 38 mm, it is the longest available DES, providing doctors an option that can potentially reduce the number of stents used in more complex cases, simplifying procedures and reducing costs. It affords a more efficient treatment option for the estimated 8 to 10 percent(1) of patients with long lesions. Boston Scientific plans to launch the product in the U.S. next month. It received CE Mark approval in 2007.

"The TAXUS Liberte Long Stent offers physicians and patients distinct advantages compared to using two overlapping drug-eluting stents," said Mark Turco, M.D., FACC, FSCAI, Director of the Center for Cardiac Vascular Research at Washington Adventist Hospital, Takoma Park, Maryland. "In the ATLAS Long Lesion Trial, the 38 mm TAXUS Liberte Stent significantly reduced myocardial infarction when compared to the TAXUS(R) Express(R) Stent, making the TAXUS Liberte Long Stent an attractive option for interventional cardiologists faced with long, challenging lesions."

The TAXUS ATLAS Long Lesion Trial reported a significant 79 percent reduction in the rate of nine-month myocardial infarction for the TAXUS Liberte Long Stent as compared to the TAXUS Express Stent control (1.3% vs. 6.3%, p=0.026). At two years, the composite measure of cardiac death or myocardial infarction showed a significant 63 percent reduction for the TAXUS Liberte Long Stent compared to
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... September 04, 2015 , ... Canadian astronomer David Levy — who discovered ... maintained for nearly 60 years to the Linda Hall Library . , ... Jupiter in 1994 — an episode that produced the first collision between two solar ...
(Date:9/4/2015)... , Sep. 04, 2015 ... announced the addition of the "Biopreservation Market ... Global Forecast to 2020" report to their ... expected to reach USD 3,731.03 Million by 2020 ... a CAGR of 11.65% between 2015 and 2020. ...
(Date:9/4/2015)... ... September 04, 2015 , ... BioBots ... BioBot 1, at the 2015 TERMIS World Congress in Boston. The launch comes ... engineering institutions around the world. The printer is revolutionary for its compact design, ...
(Date:9/4/2015)... San Francisco, CA (PRWEB) , ... September 04, ... ... in the delivery of product safety and pharmacovigilance services and software tools to ... software application, PRIMO Mobile by Allergan Japan. PRIMO Mobile is a mobile data ...
Breaking Biology Technology:Renowned Astronomer David Levy To Donate Night Sky Observation Logs to the Linda Hall Library 2Renowned Astronomer David Levy To Donate Night Sky Observation Logs to the Linda Hall Library 3Global Biopreservation Market 2015-2020 - Product, Biospecimen, Application and End User Analysis of the $3.73 Billion Industry 2Global Biopreservation Market 2015-2020 - Product, Biospecimen, Application and End User Analysis of the $3.73 Billion Industry 3BioBots to Debut Desktop 3D Bioprinter for Living Tissue at TERMIS Global Tissue Engineering Conference in Boston 2BioBots to Debut Desktop 3D Bioprinter for Living Tissue at TERMIS Global Tissue Engineering Conference in Boston 3BioBots to Debut Desktop 3D Bioprinter for Living Tissue at TERMIS Global Tissue Engineering Conference in Boston 4November Research Group’s PRIMO Mobile Goes Live at Allergan Japan 2
... DURHAM, N.C., Sept. 9 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: ... asks shareholders to approve a 1-for-15 reverse stock split at the ... "At last years, general annual meeting we explained the problems of ... promised to seek a listing change as soon as we can ...
... , WILMINGTON, N.C., Sept. 9 Wilmington ... (FDA) has granted marketing approval for METOZOLV((TM)) ODT (metoclopramide ... treatment of gastroesophageal reflux disease (GERD) and diabetic gastroparesis. ... a specialty pharmaceutical company with a focus on gastrointestinal ...
... WILMINGTON, N.C., Sept. 9 Jim Robison has been ... of several new Sanford Rose Associates executive search offices opening ... McGill Environmental Systems and CFO of House of Raeford Farms. ... rapidly growing agribusiness, food processing, and distribution companies, Robison is ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split 2Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 2Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 3Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 4Sanford Rose Associates Opens Wilmington, N.C. Office 2
(Date:9/2/2015)... 2015 Biometric technology ... a system which uses identical human characteristic such ... DNA and finger print. Increasing number of terror ... system which provides high level of security. Traditional ... tokens are vulnerable to attacks. Furthermore, Biometric technology ...
(Date:8/31/2015)... 31, 2015 Growing need for ... government digitization projects to drive India ... TechSci Research report, " India Biometrics Market Forecast & Opportunities, ... is projected to grow at a CAGR of over 35% ... on account of extensive use of biometric technology in the ...
(Date:8/28/2015)... August 28, 2015 According to ... Market by Assessment Type (Pen & Paper Based, Hosted, ... Corporate Learning, Academic Research), Vertical and Region - Global ... Training Market to grow from USD 2.4 Billion in ... Compound Annual Growth Rate (CAGR) of 25.6% from 2015 ...
Breaking Biology News(10 mins):Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4
... have received a $3.3 million contract from the U.S. Defense ... will be so soft and squishy that they will be ... then morph back into something 10 times larger, and ultimately ... to conduct dangerous or difficult operations are clear, and the ...
... The tummy,s taste for red wine with red ... What happens when red wine meets red meat? If ... reporting, wine,s bounty of healthful chemical compounds may thwart formation ... meat. The study, which reinforces the benefits of consuming wine ...
... the 75 million Americans with essential hypertension also develop ... blood pressure, and researchers have discovered a common molecular ... such metabolic disorders arise together in mammals. , The ... Engineering also showed that a drug developed for unrelated ...
Cached Biology News:Tufts to develop morphing 'chemical robots' 2Tufts to develop morphing 'chemical robots' 3American Chemical Society's Weekly PressPac -- June 25, 2008 2American Chemical Society's Weekly PressPac -- June 25, 2008 3American Chemical Society's Weekly PressPac -- June 25, 2008 4American Chemical Society's Weekly PressPac -- June 25, 2008 5American Chemical Society's Weekly PressPac -- June 25, 2008 6American Chemical Society's Weekly PressPac -- June 25, 2008 7American Chemical Society's Weekly PressPac -- June 25, 2008 8American Chemical Society's Weekly PressPac -- June 25, 2008 9A single mechanism for hypertension, insulin resistance and immune suppression 2A single mechanism for hypertension, insulin resistance and immune suppression 3A single mechanism for hypertension, insulin resistance and immune suppression 4
Mouse monoclonal [DJR3] to DcR1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Request Info...
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
Biology Products: